Raphael Pharmaceutical (RAPH) Long-Term Deferred Tax (2020 - 2025)

Raphael Pharmaceutical has disclosed Long-Term Deferred Tax across 6 years of filings, most recently posting $8.8 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax rose 26.81% year-over-year to $8.8 million; the TTM figure through Dec 2025 stood at $8.8 million (up 26.81% YoY), while the FY2025 annual figure was $8.8 million, up 26.81% from the prior year.
• Long-Term Deferred Tax came in at $8.8 million for Q4 2025 at Raphael Pharmaceutical, up from $7.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $8.8 million in Q4 2025 to a low of $3.2 million in Q4 2022.
• Average Long-Term Deferred Tax over 5 years is $6.1 million, with a median of $5.7 million recorded in 2021.
• Year-over-year, Long-Term Deferred Tax soared 736.39% in 2021 and sank 44.31% in 2022.
• Over 5 years, Long-Term Deferred Tax stood at $5.7 million in 2021, then slumped by 44.31% to $3.2 million in 2022, then soared by 79.41% to $5.7 million in 2023, then increased by 21.32% to $7.0 million in 2024, then increased by 26.81% to $8.8 million in 2025.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $8.8 million in Q4 2025, $7.0 million in Q4 2024, and $5.7 million in Q4 2023.